日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

作者更正:sacituzumab govitecan治疗转移性三阴性乳腺癌的3期ASCENT试验安全性分析

Rugo, Hope S; Tolaney, Sara M; Loirat, Delphine; Punie, Kevin; Bardia, Aditya; Hurvitz, Sara A; O'Shaughnessy, Joyce; Cortés, Javier; Diéras, Véronique; Carey, Lisa A; Gianni, Luca; Piccart, Martine J; Loibl, Sibylle; Goldenberg, David M; Hong, Quan; Olivo, Martin; Itri, Loretta M; Kalinsky, Kevin

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas

Sacituzumab govitecan联合铂类化疗对三阴性乳腺癌、膀胱癌和小细胞肺癌具有显著的抗肿瘤作用。

Cardillo, Thomas M; Zalath, Maria B; Arrojo, Roberto; Sharkey, Robert M; Govindan, Serengulam V; Chang, Chien-Hsing; Goldenberg, David M

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

来自转移性三阴性乳腺癌患者接受sacituzumab govitecan治疗的3期ASCENT试验的安全性分析

Rugo, Hope S; Tolaney, Sara M; Loirat, Delphine; Punie, Kevin; Bardia, Aditya; Hurvitz, Sara A; O'Shaughnessy, Joyce; Cortés, Javier; Diéras, Véronique; Carey, Lisa A; Gianni, Luca; Piccart, Martine J; Loibl, Sibylle; Goldenberg, David M; Hong, Quan; Olivo, Martin; Itri, Loretta M; Kalinsky, Kevin

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

抗CEA预靶向免疫PET在检测复发性转移性甲状腺髓样癌方面比DOPA PET/CT具有更高的敏感性:iPET-MTC研究的事后分析

Bodet-Milin, Caroline; Faivre-Chauvet, Alain; Carlier, Thomas; Ansquer, Catherine; Rauscher, Aurore; Frampas, Eric; Toulgoat, Frederique; Masson, Damien; Bourgeois, Mickael; Cerato, Evelyne; Rohmer, Vincent; Couturier, Olivier; Drui, Delphine; Goldenberg, David M; Sharkey, Robert M; Barbet, Jacques; Kraeber-Bodere, Francoise

Ex Vivo Assessment of Tumor-Targeting Fluorescent Tracers for Image-Guided Surgery

体外评估用于图像引导手术的肿瘤靶向荧光示踪剂

Elekonawo, Fortuné M K; de Gooyer, Jan Marie; Bos, Desirée L; Goldenberg, David M; Boerman, Otto C; Brosens, Lodewijk A A; Bremers, Andreas J A; de Wilt, Johannes H W; Rijpkema, Mark

Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases

针对代谢PET和免疫PET阳性椎体转移瘤的立体定向放射治疗

Pichon, Baptiste; Rousseau, Caroline; Blanc-Lapierre, Audrey; Delpon, Gregory; Ferrer, Ludovic; Libois, Vincent; Le Turnier, Matthieu; Lenoble, Cédric; Bodet-Milin, Caroline; Goldenberg, David M; Kraeber-Bodere, Françoise; Supiot, Stéphane

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)

更正:Trop-2 是 sacituzumab govitecan (IMMU-132)(一种抗体药物偶联物 (ADC))治疗实体瘤的新靶点。

Goldenberg, David M; Cardillo, Thomas M; Govindan, Serengulam V; Rossi, Edmund A; Sharkey, Robert M

Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

新型免疫PET诊疗探针在人表皮生长因子受体2阴性乳腺癌中的初步临床结果

Rousseau, Caroline; Goldenberg, David M; Colombié, Mathilde; Sébille, Jean-Charles; Meingan, Philippe; Ferrer, Ludovic; Baumgartner, Pierre; Cerato, Evelyne; Masson, Damien; Campone, Mario; Rauscher, Aurore; Fleury, Vincent; Labbe, Catherine; Chauvet, Alain Faivre; Fresnel, Jean-Sebastien; Toquet, Claire; Barbet, Jacques; Sharkey, Robert M; Campion, Loic; Kraeber-Bodéré, Françoise

A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer

在异种移植结直肠癌模型中,采用预靶向多模态方法进行图像引导切除

Elekonawo, Fortuné M K; Lütje, Susanne; Franssen, Gerben M; Bos, Desirée L; Goldenberg, David M; Boerman, Otto C; Rijpkema, Mark

Carcinoembryonic antigen-targeted photodynamic therapy in colorectal cancer models

癌胚抗原靶向光动力疗法在结直肠癌模型中的应用

Elekonawo, Fortuné M K; Bos, Desirée L; Goldenberg, David M; Boerman, Otto C; Rijpkema, Mark